Jobs
View more job listings or post a job
Jazz Pharmaceuticals Senior Manager, Clinical Pharmacology
Nektar Therapeutics Research Associate III
Nektar Therapeutics Sr. Scientist, Bioanalytical
Genentech, Inc. Associate Scientist/Scientist, Drug Metabolism and Pharmacokinetics
Jubilant Discovery Services Senior Manager Business Development
Aimmune Therapeutics The Associate Director, Quality Control will be a key member of the analytical team and he/she will support activities associated with quality control activities of Aimmune’s APIs and drug products conducted at CTL/CMO.  
Precision for Medicine Senior Manager, Quality Assurance
Denali Therapeutics Bioanalytical Research Scientist, DMPK (SM/Biomarker)
Arena Pharmaceuticals The Principal Scientist will report to the Head of Analytical Sciences and will serve as the analytical lead in cross-functional product development tea
Genentech Associate Scientist/Scientist, Process Analytical Technology, Small Molecule Analytical Chemistry  
Post a job

Symposium

Drug-Induced Liver Injury (DILI): Risk Assessment of Drug Candidates and Metabolites in Drug Discovery and Clinical Development


Speakers: William Treem (J&J), Michael Rothenberg (Genentech), Weida Tong (NCTR/FDA), Yazen Alnouti (UNMC), Donna Dambach (Genentech), Cyrus Khojasteh (Genentech), Kenneth Brouwer (Qualyst), Gary Peltz (Stanford University Medical School)
Organizers: Cyrus Khojasteh and Will Proctor (Genentech)
Date: 2017-06-02
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $125; Students or Unemployed: $35
Location: Crowne Plaza, Foster City, CA
Major Sponsor:
Vendor show vendors registered to date: (12)BioDuro; BioreclamationIVT; Cellular Dynamics Intl; Cyprotex; Cytovier LLC; Hurel Corporation; Lonza; Optivia Biotechnology; Organovo; Qualyst Transporter Solutions, LLC; SOLVO Biotechnology; XenoTech
Registration: http://www.PBSS.org
Registration deadline:2017-05-30  (it will close sooner if the seating cap is reached)

About the Topic

Drug-induced liver injury (DILI) continues to be a leading cause of attrition during small molecule drug development, withdrawal post-marketing, and cautionary / restrictive labeling. Hepatotoxicity risk is difficult to predict based on the various etiologies that encompass DILI, with unknown factors driving patient susceptibility towards hepatic stress and injury, coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo. However, retrospective analysis over the past 50 years has identified several factors associated with DILI that include but are not limited to physicochemical properties of the drug, dose, metabolism and disposition, and signals in a battery of in vitro assays.  As such, the pharmaceutical industry and regulatory agencies alike are focused on more comprehensive risk assessment to reduce and/or mitigate DILI risk in drug discovery and early development.  

This full-day mini-symposium is centered on contemporary perspectives on DILI from an academic, industry, and regulatory perspective, with focused talks addressing mechanisms of DILI, clinical presentation and management, hepatotoxicity risk assessment in drug discovery, and novel tools (including biomarkers) emerging in the field.

 

Agenda 

8:45am - 8:50am     PBSS Welcome Organizer

8:50am – 9:00am

  • General Introduction to the DILI Workshop (Will Proctor, PhD, Genentech)

9:00am - 9:40am

  • Filling in the Guidance Gaps and Defining Best Practices in monitoring for and diagnosing DILI in clinical trials: The IQ-DILI Consortium (William Treem, MD, J&J) 

9:40am – 10:20am

  • The challenges of potential DILI in early clinical development (Michael Rothenberg, MD, PhD, Genentech)
10:20am - 10:45am     Break   

 10:45am – 11:25am

  • Liver Toxicity Knowledge Base – A knowledge base approach for drug-induced liver injury (Weida Tong, PhD, NCTR/FDA)

 11:25am – 12:00pm

  • The role of bile acids in DILI and liver diseases (Yazen Alnouti, PhD, University of Nebraska Medical Center (UNMC))

 12:00pm - 1:00pm     Lunch   

 1:00pm – 1:40pm

  • Multi-parametric assessment of hepatotoxicity risk in drug discovery (Donna Dambach, VMD, PhD, Genentech)

 1:40pm – 2:20pm

  • Reactive metabolites: from assessment to removal in drug discovery (Cyrus Khojasteh, PhD, Genentech)

 2:20pm - 2:45pm     Break   

 2:45pm – 3:25pm

  • Risk Assessment for Cholestatic Hepatotoxicity: Integrating Transporter Inhibition and FXR Mediated Regulation into a Predictive In Vitro Assay (Kenneth R. Brouwer, PhD, RPh, Qualyst Transporter Solutions)

 3:25pm – 4:05pm

  • Human Liver Engineering: From Safer Drugs to Liver Regeneration      (Gary Peltz, MD, PhD, Stanford University Medical School)

 4:05pm – 4:45pm

  • Panel Discussion (All Speakers)


2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics (IVD), Companion Diagnostics (CDx) and Precision Medicine
2020-01-10, All about half-life: which one should I use? (tentative title)
2020-01-21, Considerations for Successful Clinical Development: Fundamentals and Best Practices for Clinical Trial Design, Biostatistics, and Data Management
2020-02-11, Development of Drug/Device Combinations
2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2020-04-10, Biopolymer-based conjugation of therapeutic proteins and antibodies for improving drug properties (tentative title)
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 10/20/2019; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Adesis Inc. Adesis provides expertise in custom synthesis, process dev, R&D, and specialty mfg. to pharma, chemical, biomaterials, and catalysts companies
UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: http://50.73.55.13/counter.php?id=165482 UC Davis is an AA/EOE
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS & GC-MS/MS bioanalytical quantitation services of small & large molecules in any matrix. Discovery through phase IV.
Origin Bioanalytical Laboratory Sacramento-based CRO for bioanalytical method development, validation, and consulting of LC-MS/MS analysis, specializing in ocular matrices
Submit a Text Ad